GlaxoSmithKline Intellectual Property Development Limited (United Kingdom)
Inventor
Guang, Jie
Washburn, David Glenn
Abstract
Compounds of formula (1) are described, wherein each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (1), and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, disorders, and conditions, such as pain and pain-associated diseases, disorders, and conditions and cardiovascular diseases, disorders, and conditions.
Compounds of formula (1) are described, wherein each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (1), and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, disorders, and conditions, such as pain and pain-associated diseases, disorders, and conditions and cardiovascular diseases, disorders, and conditions.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Anti-infectives; Vaccines
A method for immunizing a subject in need thereof against Neisseria gonorrhoeaeby administering an immunogenic composition comprising meningococcal outer membrane vesicles (OMVs).
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
6.
CYTOTOXICITY TARGETING CHIMERAS FOR FIBROBLAST ACTIVATION PROTEIN-EXPRESSING CELLS
Glaxosmithkline Intellectual Property Development Limited (United Kingdom)
Inventor
Di Marco, Christina Ng
Sender, Matthew Robert
Turunen, Brandon James
Abstract
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
The present invention is in the field of treating and/or preventing viral infections. In particular, the present invention relates to immunogenic or pharmaceutical compositions comprising self-replicating RNA molecules that encode influenza virus antigens for treating and/or preventing influenza infections.
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (United Kingdom)
Inventor
Catalano, John G.
Chong, Pek Yoke
Dickson, Hamilton D.
Leivers, Martin R.
Weatherhead, Jason Gordon
Abstract
Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.
The invention relates to a novel method of controlling the glycosylation profile of an antibody. In particular, the method involves the use of trace metal ions, specifically manganese and copper, in defined amounts in antibody-producing cell cultures.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
11.
CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (United Kingdom)
Inventor
Chen, Peiling
Darcy, Michael Gerard
Dodson, Jason W.
Knapp-Reed, Beth Anne
Marino, Jr., Joseph Paul
Oplinger, Jeffrey Alan
Sender, Matthew Robert
Turunen, Brandon James
Ye, Guosen
Zhang, Cunyu
Abstract
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
12.
CYTOTOXICITY TARGETING CHIMERAS FOR PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CELLS
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (United Kingdom)
Inventor
Di Marco, Christina Ng
Sender, Matthew Robert
Turunen, Brandon James
Abstract
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07K 16/16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from plants
Methods of preventing or treating liver disease in a subject characterised as having a PNPLA3- 148M protein variant are provided. The methods include administering to the subject an oligonucleotide or a DNA molecule encoding an oligonucleotide, wherein the oligonucleotide is capable of effecting ADAR-mediated editing of a polynucleotide encoding the PNPLA3-148M protein variant, and wherein the polynucleotide encoding the PNPLA3-148M protein variant undergoes ADAR-mediated editing at a codon encoding the methionine at position 148 such that the polynucleotide encodes a PNPLA3-148V protein variant. The disclosure also provides methods of editing a target ribonucleic acid (RNA) molecule encoding a PNPLA3-148M protein variant and methods of restoring the function of the PNPLA3 protein in a subject characterised as having the PNPLA3-148M protein variant.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders; pharmaceutical preparations for the prevention and treatment of auto-immune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, pulmonary, cardiorenal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the treatment of blood diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle cell disease, anaemia, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases; pharmaceutical preparations for the treatment of connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, ligament injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin infections namely acne, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of irritable bowel disorders and symptoms, digestive disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrhea and infertility; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of inflammatory pelvic diseases, vasomotor symptoms, menopausal symptoms, endometriosis, uterine fibroids and Leiomyoma; pharmaceutical preparations and substances for use in urology, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases; pharmaceutical preparations for the treatment of hepatological diseases and disorders; pharmaceutical preparations for the treatment of hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, cirrhosis, cholestatic pruritus and primary biliary cholangitis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia and psychoses; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; Allergy medications; Vaccines for human use; pharmaceutical preparations for the treatment of central nervous system and neurological diseases and disorders namely Parkinsons Disease, Alzheimers Disease, Huntingtons Disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory pain, fibromyalgia, stroke, multiple sclerosis, insomnia; pharmaceutical preparations for the treatment of muscular dystrophy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of nephrological related diseases and disorders
The invention provides an immunogenic composition comprising OMVs and (a) acellular pertussis antigen, (b) a tetanus toxoid and (c) a diphtheria toxoid, wherein the OMVs are derived from Bordetella pertussis. The invention also provides compositions for use in a method for raising an immune response in a patient, comprising the step of administering to the patient a composition of the invention.
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (United Kingdom)
Inventor
Di Marco, Christina Ng
Sender, Matthew Robert
Turunen, Brandon James
Abstract
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, or autoimmune diseases.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Candida albicansCandida albicans') protein. The modified Sap2 protein can be used as a carrier protein for other antigens, particularly saccharide antigens or other antigens lacking T cell epitopes.
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (United Kingdom)
Inventor
Turunen, Brandon James
Zhang, Cunyu
Abstract
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, or autoimmune diseases.
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
Candida albicansCandida albicans) protein. The modified Als3 protein can be used as a carrier protein for other antigens, particularly saccharide antigens or other antigens lacking T cell epitopes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives
The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.
A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
24.
INTERLEUKIN 5 BINDING PROTEIN DOSAGE REGIMEN FOR USE IN TREATING POLYANGIITIS, HYPEREOSINOPHILIC SYNDROME, CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP), OR CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS (CRSSNP)
GlaxoSmithKline Intellectual Property Development Limited (United Kingdom)
Inventor
Austin, Daren J.
Berges, Alienor C.
Bird, Nicholas P.
Monck, Myrna A.
Pouliquen, Isabelle J.
Shuman, Melissa A.
Zecchin, Chiara
Abstract
The present disclosure relates to pharmaceutical compositions comprising from about 100 mg to about 300 mg of an antigen binding protein which binds to IL-5. Compositions and antigen binding proteins of the disclosure are useful in the treatment of IL-5 mediated diseases, such as EGPA, HES, CRSsNP and CRSwNP, and can be administered about once every 6 months.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives
The present invention relates to an aminotransaminase useful in the synthesis of (R)-3-aminobutan-1-ol (RABO). The present invention also provides a process of preparing (R)-3-aminobutan-1-ol (RABO) with the disclosed aminotransaminase.
The present invention relates to immunogenic compositions comprising outer membrane vesicles (OMVs) adsorbed to an aluminium hydroxide adjuvant, whereby the aluminium hydroxide adjuvant is quenched. The present invention also relates to the use of the immunogenic compositions for providing protection against diseases caused by Gram-negative bacteria. The present invention also relates to a method for reducing particle aggregation and/or average particle diameter in compositions comprising OMVs and an aluminium hydroxide adjuvant.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
The present invention relates to conjugates comprising polysaccharides comprising 3- deoxy-D-manno-actulosonic acid (KDO) moieties, particularly conjugates produced using random conjugation methods, methods for preparing such conjugates, immunogenic compositions and vaccines comprising the conjugates, and methods of treatment or medical uses using the compositions and vaccines.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present invention relates to immunogenic compositions comprising antigens from Salmonella enterica serovar Typhimurium (S. Typhimurium), Salmonella enterica serovar Enteritidis (S. Enteritidis), and Salmonella enterica serovar Typhi (S. Typhi). The present invention further relates to methods and uses of compositions comprising GMMA for boosting an immune response to an S. Typhi antigen, vaccines comprising the immunogenic compositions and methods and uses of the immunogenic compositions.
The present invention provides lyophilised pharmaceutical compositions and processes of making said lyophilised pharmaceutical compositions. More particularly, the present invention provides lyophilised pharmaceutical compositions comprising lipid nanoparticles encapsulating a nucleic acid payload wherein the lyophilised pharmaceutical composition is in the form of a plurality of lyophilised beads (LyoBeads) and processes for making said compositions. The present invention further provides the use of said lyophilised pharmaceutical compositions in medicine.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
The present disclosure provides T7 RNA polymerase variants, the use of which increases transcription efficiency and improves the quality and yield of the enzyme. Also provided are polynucleotides encoding the T7 RNA polymerase variants, host cells capable of expressing the T7 RNA polymerase variants, and methods of using the T7 RNA polymerase variants for high-efficiency transcription.
The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present Invention relates to pharmaceutical compositions of (3S,11aR)-N-[(2,4-difluorophenyl)methyl]2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d] pyrazine-8-carboxamide, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.
The present Invention relates to pharmaceutical compositions of (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
43.
MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES
Described are mutant, human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Tooth powders; tooth care preparations; teeth and artificial teeth cleaning preparations; toothpaste; preparations and substances for cleaning, washing, polishing, deodorising dentures; denture cleaners, dentifrices, non-medicated mouth rinses, mouth sprays, non-medicated mouth wash preparations; breath fresheners; deodorants for personal use; products included in Class 3 for oral care and oral hygiene.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Tooth powders; tooth care preparations; teeth and artificial teeth cleaning preparations; toothpaste; preparations and substances for cleaning, washing, polishing, deodorising dentures; denture cleaners, dentifrices, non-medicated mouth rinses, mouth sprays, non-medicated mouth wash preparations; breath fresheners; deodorants for personal use; products included in Class 3 for oral care and oral hygiene.
47.
IL-7 Binding Proteins and Their Use in Medical Therapy
GlaxoSmithKline Intellectual Property Development Limited (United Kingdom)
Inventor
Bouma, Gerben
Coulstock, Edward Thomas
Dixon, David
Hopley, Stephanie
Lewis, Alan Peter
Neisen, Jessica Lynn
Abstract
Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A method of immunizing a human female subject to decrease the risk of Group B Streptococcus (GBS) disease in an infant born to the subject, by providing a priming dose of a GBS vaccine and, more than thirty days after the priming dose, providing a boosting dose of a GBS vaccine.
The disclosure relates to therapeutic methods or methods of treating, clearing, preventing or curing Human Immunodeficiency Virus (HIV) infection. The disclosure provides a combination of at least one agent selected from the group consisting of: fostemsavir and temsavir, or a pharmaceutically acceptable salt thereof and a CD4 binding site (CD4bs) binding protein for the use in treatment of HIV and/or clearance of HIV infected cells.
inter alia inter alia, an RSV-F protein comprising at least two mutations relative to SEQ ID NO: 1 or 3 within a region of the protein corresponding to positions 474-523 of SEQ ID NO: 1 or 3; wherein the at least two mutations introduce, through substitution or insertion, a pair of C residues into the region, which form a disulphide bond.
RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus, the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
54.
HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (United Kingdom)
UNIVERSITY OF DUNDEE (United Kingdom)
Inventor
Bates, Robert
Cleghorn, Laura
Davis, Susan
Green, Kirsteen
Green, Simon
Harrison, Justin
Jimenez Navarro, Elena
Koovits, Paul
Wyatt, Paul
Abstract
The invention relates to compounds or pharmaceutically acceptable salts thereof, compositions containing them, including combinations with at least one additional therapeutic agent, and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by a mycobacterium, such as tuberculosis.
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61P 31/06 - Antibacterial agents for tuberculosis
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders; pharmaceutical preparations for the prevention and treatment of auto-immune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, pulmonary, cardiorenal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders, namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the treatment of blood diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle cell disease, anaemia, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases; pharmaceutical preparations for the treatment of connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, ligament injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin infections namely acne, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of irritable bowel disorders and symptoms, digestive disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrhea and infertility; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of inflammatory pelvic diseases, vasomotor symptoms, menopausal symptoms, endometriosis, uterine fibroids and Leiomyoma; pharmaceutical preparations and substances for use in urology, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases; pharmaceutical preparations for the treatment of hepatological diseases and disorders; pharmaceutical preparations for the treatment of hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, cirrhosis, cholestatic pruritus and primary biliary cholangitis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia and psychoses; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; allergy medications; vaccines for human use; pharmaceutical preparations for the treatment of central nervous system and neurological diseases and disorders namely Parkinsons Disease, Alzheimers Disease, Huntingtons Disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory pain, fibromyalgia, stroke, multiple sclerosis, insomnia; pharmaceutical preparations for the treatment of muscular dystrophy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of nephrological related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders; pharmaceutical preparations for the prevention and treatment of auto-immune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, pulmonary, cardiorenal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the treatment of blood diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle cell disease, anaemia, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases; pharmaceutical preparations for the treatment of connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, ligament injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin infections namely acne, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of irritable bowel disorders and symptoms, digestive disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders, namely amenorrhoea, dysmenorrhea and infertility; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of inflammatory pelvic diseases, vasomotor symptoms, menopausal symptoms, endometriosis, uterine fibroids and Leiomyoma; pharmaceutical preparations and substances for use in urology, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases; pharmaceutical preparations for the treatment of hepatological diseases and disorders; pharmaceutical preparations for the treatment of hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, cirrhosis, cholestatic pruritus and primary biliary cholangitis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia and psychoses; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; allergy medications; vaccines for human use; pharmaceutical preparations for the treatment of central nervous system and neurological diseases and disorders, namely Parkinsons Disease, Alzheimers Disease, Huntingtons Disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory pain, fibromyalgia, stroke, multiple sclerosis, insomnia; pharmaceutical preparations for the treatment of muscular dystrophy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of nephrological related diseases and disorders.
The present invention relates to an IBAT inhibitor for use in the treatment of pruritus in certain chronic liver diseases such as non-alcoholic fatty liver disease (NAFLD) [newly reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD)] which encompasses non- alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) [newly reclassified as metabolic dysfunction-associated steatohepatitis (MASH)] with or without cirrhosis, and methods of treatment of pruritus in NAFLD (or MASLD), including NAFL and NASH (or MASH) with or without cirrhosis, comprising administering to said human a therapeutically effective amount of an IBAT inhibitor such as linerixibat.
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of amaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious disease; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
The instant disclosure provides methods of treating or preventing a SARS-CoV-2 infection in a pediatric subject, e.g., in a pediatric subject having or at risk for developing COVID-19, wherein the methods include administering an antibody, antigen-binding fragment, or composition comprising the same to a pediatric subject. Disclosed methods include prophylactic administration for preventing SARS-CoV-2 infection or transmission, as well as treatment of a pediatric subject having a SARS-CoV-2 infection. A SARS-CoV-2 infection (e.g., causing COVID-19) to be treated can be at any stage of infection and/or can result in any stage of disease, for example, mild, mild-to-moderate, severe, or critical.
Disclosed herein are certain chemical compounds that inhibit Werner Syndrome ATP dependent helicase enzyme (WRN) activity, in particular inhibit WRN helicase domain activity and are therefore useful in treating cancers treatable by inhibition of WRN, including cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR). Also, disclosed are pharmaceutical compositions comprising such compounds, methods of using such compounds, and methods making the same.
C07D 235/08 - Radicals containing only hydrogen and carbon atoms
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Disclosed are crystalline and amorphous forms of linerixibat and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof. Also disclosed is solubility and dissolution information for linerixibat.
C07D 281/10 - Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
89.
METHODS FOR ELICITING AN IMMUNE RESPONSE TO RESPIRATORY SYNCYCIAL VIRUS AND STREPTOCOCCUS PNEUMONIAE INFECTION
Provided herein are methods, immunogenic combinations, immunogenic compositions, and uses thereof directed to co-administration of an immunogenic composition comprising a recombinant RSV antigen comprising a soluble F protein comprising at least one modification that stabilizes the prefusion conformation of the F protein; and an immunogenic composition comprising at least one glycoconjugate from each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, epstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders; pharmaceutical preparations for the prevention and treatment of auto-immune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, pulmonary, cardiorenal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the treatment of blood diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle cell disease, anaemia, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases; pharmaceutical preparations for the treatment of connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, ligament injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin infections namely acne, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of irritable bowel disorders and symptoms, digestive disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrhea and infertility; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of inflammatory pelvic diseases, vasomotor symptoms, menopausal symptoms, endometriosis, uterine fibroids and leiomyoma; pharmaceutical preparations and substances for use in urology, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases; pharmaceutical preparations for the treatment of hepatological diseases and disorders; pharmaceutical preparations for the treatment of hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, cirrhosis, cholestatic pruritus and primary biliary cholangitis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia and psychoses; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; allergy medications; vaccines for human use; pharmaceutical preparations for the treatment of central nervous system and neurological diseases and disorders namely parkinsons disease, alzheimers disease, huntingtons disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory pain, fibromyalgia, stroke, multiple sclerosis, insomnia; pharmaceutical preparations for the treatment of muscular dystrophy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of nephrological related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, epstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders; pharmaceutical preparations for the prevention and treatment of auto-immune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, pulmonary, cardiorenal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the treatment of blood diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle cell disease, anaemia, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases; pharmaceutical preparations for the treatment of connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, ligament injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin infections namely acne, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of irritable bowel disorders and symptoms, digestive disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrhea and infertility; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of inflammatory pelvic diseases, vasomotor symptoms, menopausal symptoms, endometriosis, uterine fibroids and leiomyoma; pharmaceutical preparations and substances for use in urology, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases; pharmaceutical preparations for the treatment of hepatological diseases and disorders; pharmaceutical preparations for the treatment of hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, cirrhosis, cholestatic pruritus and primary biliary cholangitis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia and psychoses; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; allergy medications; vaccines for human use; pharmaceutical preparations for the treatment of central nervous system and neurological diseases and disorders namely parkinsons disease, alzheimers disease, huntingtons disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory pain, fibromyalgia, stroke, multiple sclerosis, insomnia; pharmaceutical preparations for the treatment of muscular dystrophy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of nephrological related diseases and disorders.
92.
MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES
Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.
The present disclosure provides anti-BlyS antibodies for use in the treatment of connective tissue disease, in particular, connective tissue disease-associated interstitial lung disease, including systemic sclerosis, in particular, systemic sclerosis associated interstitial lung disease, for example, diffuse cutaneous systemic sclerosis-associated interstitial lung disease. Also provided is a method for the treatment of connective tissue disease-associated interstitial lung disease, including systemic sclerosis associated-interstitial lung disease comprising administering to a subject in need thereof a therapeutically effective amount of an anti-BlyS antibody.
A61P 11/00 - Drugs for disorders of the respiratory system
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to a process for the production of purified O-polysaccharide-Exoprotein A (O-EPA) bioconjugates. In particular, the process comprises a purification of said bioconjugate comprising the steps of a first anion exchange chromatography prior to a hydroxyapatite chromatography followed by a hydrophobic interaction chromatography and subsequently a second anion exchange chromatography.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of COVID-19, coronavirus disease and respiratory diseases and disorders; vaccines for prevention of COVID-19, coronavirus disease
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (United Kingdom)
Inventor
Bhugra, Chandan
Borkar, Shavari
Oh, Yoon
Pan, Rennan
Abstract
Disclosed are novel pharmaceutical compositions comprising gepotidacin, such as gepotidacin mesylate dihydrate, gepotidacin mesylate anhydrate or gepotidacin anhydrate. The present disclosure also provides methods for making the pharmaceutical composition comprising gepotidacin, and methods of treating bacterial infections using such pharmaceutical composition.
GlaxoSmithKline Intellectual Property Development Limited (United Kingdom)
Inventor
Davis, Tyler Keith
Schuessler, Hillary Amber
Abstract
Disclosed herein are stable isotope labeling (SIL) peptide mapping methods for accurate and sensitive conjugation site quantitation. Also disclosed herein are compositions comprising antibody drug conjugates (ADCs) that target BCMA.
